Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

CTSO has been the subject of several other research reports. HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Tuesday, May 7th. B. Riley restated a “buy” rating and issued a $3.00 price target on shares of Cytosorbents in a research note on Wednesday, May 15th.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $1.19 on Monday. The stock has a market cap of $64.36 million, a PE ratio of -2.01 and a beta of 0.58. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $3.73. The firm has a fifty day moving average price of $0.92 and a 200-day moving average price of $0.93. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.49 and a quick ratio of 1.21.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $9.79 million during the quarter, compared to analyst estimates of $9.78 million. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. During the same quarter in the prior year, the business posted ($0.17) EPS. Equities analysts anticipate that Cytosorbents will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Several hedge funds have recently bought and sold shares of the stock. Raymond James & Associates bought a new stake in shares of Cytosorbents in the fourth quarter worth about $56,000. Key Client Fiduciary Advisors LLC grew its holdings in Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares in the last quarter. Skylands Capital LLC increased its stake in Cytosorbents by 10.5% in the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after acquiring an additional 309,543 shares during the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares in the last quarter. Finally, Avenir Corp boosted its position in shares of Cytosorbents by 12.3% during the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after acquiring an additional 334,005 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.